FDA Awards ICON with Project Validating PROs
Research is being conducted in collaboration with the FNIH Biomarkers Consortium
Dublin, Ireland – ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been awarded a project by the
HABP is the second most common hospital-acquired infection and is the primary cause of death in intensive care units; ABSSSI has high rates of morbidity and other associated medical conditions whilst CABP is a major cause of mortality and morbidity worldwide, particularly among people over 65 years of age. Sponsors engaged in clinical trials for these conditions are currently using different methodologies to assess the primary endpoint as there is no qualified PRO instrument.
ICON’s Clinical Outcomes Assessment (COA) group, in collaboration with the
The collaboration brings together scientists from ICON, FNIH, the FDA, the
“This project builds on our previous work with the FDA and FNIH to develop a new PRO measure for HABP trials and we’re proud to continue our support in this area of great unmet need,” commented Ramita Tandon, Executive Vice President, ICON Commercialisation & Outcomes. “Bacterial infections are becoming harder to treat as drug-resistant strains emerge at an increasing rate. ICON’s COA group has extensive experience in all areas of outcomes research to validate these important endpoints for antibacterial trials, speeding up the drug development process and delivering effective antibacterial medicines to patients.”
About ICON plc
ICON plc is a global provider of drug development solutions and
About the FNIH
The Foundation for the National Institutes of Health creates and manages alliances with public and private institutions in support of the mission of the NIH, the world’s premier medical research agency. The Foundation, also known as the FNIH, works with its partners to accelerate key issues of scientific study and strategies against diseases and health concerns in the United States and across the globe. The FNIH organizes and administers research projects; supports education and training of new researchers; organizes educational events and symposia; and administers a series of funds supporting a wide range of health issues. Established by Congress in 1996, the FNIH is a not-for-profit 501(c)(3) charitable organization. Further information is available at
The Biomarkers Consortium is a public-private biomedical research partnership managed by the Foundation for the National Institutes of Health (FNIH) that endeavors to develop, validate, and/or qualify biological markers (biomarkers) to speed the development of medicines and therapies for detection, prevention, diagnosis and treatment of disease and improve patient care. Further information is available at
CRF Health is the leading provider of patient-centered eSource technology and service solutions for the life sciences industry. With experience in more than 800 trials, over 100 languages and across 74 countries, CRF Health’s TrialMax platform consistently demonstrates the industry’s highest data accuracy, patient and site compliance, and patient retention.
CRF Health’s eSource solutions improve trial engagement by fitting into the lives of patients and seamlessly integrating into sites to maximize protocol compliance. The integrated TrialMax platform includes eCOA solutions for collecting PROs (Patient Reported Outcomes), ObsROs (Observer Reported Outcomes), ClinROs (Clinician or Rater Reported Outcomes), and PerfOs (Performance Outcomes), and features TrialConsent, an electronic solution for collecting informed consent in clinical trials. More information is at
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025